Teladoc Health (NYSE:TDOC) had its price target lifted by SVB Leerink from $227.00 to $246.00 in a research report sent to investors on Thursday morning, BenzingaRatingsTable reports. SVB Leerink currently has an outperform rating on the health services provider’s stock.

TDOC has been the topic of several other research reports. Wells Fargo & Co raised their price target on Teladoc Health from $105.00 to $135.00 and gave the stock an equal weight rating in a report on Thursday, April 16th. Royal Bank of Canada raised their price target on Teladoc Health from $200.00 to $235.00 and gave the stock an outperform rating in a report on Thursday. Craig Hallum raised their price target on Teladoc Health from $140.00 to $150.00 and gave the stock a hold rating in a report on Thursday, April 30th. Piper Sandler raised their price target on Teladoc Health from $220.00 to $232.00 and gave the stock an overweight rating in a report on Thursday. Finally, SunTrust Banks raised their price target on Teladoc Health from $144.00 to $200.00 and gave the stock a hold rating in a report on Wednesday, May 13th. They noted that the move was a valuation call. Fifteen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Teladoc Health presently has an average rating of Hold and an average price target of $195.04.

Shares of TDOC opened at $237.63 on Thursday. The stock has a 50 day moving average of $207.13 and a 200-day moving average of $158.76. The company has a current ratio of 6.14, a quick ratio of 6.14 and a debt-to-equity ratio of 0.45. Teladoc Health has a 52 week low of $54.58 and a 52 week high of $240.00.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, July 29th. The health services provider reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.11). The firm had revenue of $241.03 million during the quarter, compared to analyst estimates of $220.49 million. Teladoc Health had a negative return on equity of 10.23% and a negative net margin of 13.22%. Teladoc Health’s revenue was up 85.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.41) EPS. Analysts expect that Teladoc Health will post -1.41 earnings per share for the current fiscal year.

In related news, Director William H. Frist sold 370 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $180.00, for a total transaction of $66,600.00. Following the transaction, the director now directly owns 5,788 shares of the company’s stock, valued at $1,041,840. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William H. Frist sold 740 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $228.00, for a total transaction of $168,720.00. Following the transaction, the director now directly owns 6,158 shares in the company, valued at $1,404,024. The disclosure for this sale can be found here. Over the last three months, insiders sold 189,977 shares of company stock worth $36,248,032. 3.42% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in TDOC. Total Clarity Wealth Management Inc. purchased a new position in Teladoc Health during the fourth quarter valued at approximately $25,000. PrairieView Partners LLC purchased a new position in Teladoc Health during the first quarter valued at approximately $31,000. Pathstone Family Office LLC purchased a new position in Teladoc Health during the first quarter valued at approximately $31,000. Marshall Wace North America L.P. purchased a new position in Teladoc Health during the first quarter valued at approximately $35,000. Finally, Capital Advisory Group Advisory Services LLC purchased a new position in Teladoc Health during the first quarter valued at approximately $36,000. 97.14% of the stock is currently owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Read More: What is a capital gains distribution?

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.